Literature DB >> 12069536

Urea cycle disorders.

J V Leonard1, A A M Morris.   

Abstract

Most patients with urea cycle disorders who present as neonates, do so with deteriorating feeding, drowsiness and tachypnoea, following a short initial period when they appear well. The plasma ammonia should be measured at the same time as the septic screen in such patients. Ammonia levels above 200 micromol/l are usually caused by inherited metabolic diseases and it is essential to make a diagnosis for genetic counselling, even if the patients die. The aim of treatment is to lower the ammonia concentrations as fast as possible. Sodium benzoate, sodium phenylbutyrate and arginine can exploit alternative pathways for the elimination of nitrogen but haemodialysis or haemofiltration should be instituted if ammonia concentrations are >500 micromol/l or if they do not fall promptly. Long-term management involves drugs, dietary protein restriction and use of an emergency regimen during illness. Severe hyperammonaemia is usually associated with irreversible neurological damage, particularly if levels have been above 800 micromol/l for >24 hours, and the option of withdrawing treatment should be discussed with the family. Copyright 2002 Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069536     DOI: 10.1053/siny.2001.0085

Source DB:  PubMed          Journal:  Semin Neonatol        ISSN: 1084-2756


  46 in total

1.  Successful liver transplantation for argininosuccinate lyase deficiency (ASLD).

Authors:  E Robberecht; S Maesen; A Jonckheere; S Van Biervliet; D Carton
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

2.  Amino Acid Profiles in Patients with Urea Cycle Disorders at Admission to Hospital due to Metabolic Decompensation.

Authors:  S Rodney; A Boneh
Journal:  JIMD Rep       Date:  2012-10-30

3.  Treatment of Severe Protein Malnutrition After Bariatric Surgery.

Authors:  Carlijn Kuin; Floor den Ouden; Hans Brandts; Laura Deden; Eric Hazebroek; Marcel van Borren; Hans de Boer
Journal:  Obes Surg       Date:  2019-10       Impact factor: 4.129

4.  Individual variability in human blood metabolites identifies age-related differences.

Authors:  Romanas Chaleckis; Itsuo Murakami; Junko Takada; Hiroshi Kondoh; Mitsuhiro Yanagida
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

5.  Sodium benzoate, a food additive and a metabolite of cinnamon, modifies T cells at multiple steps and inhibits adoptive transfer of experimental allergic encephalomyelitis.

Authors:  Saurav Brahmachari; Kalipada Pahan
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

Review 6.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

7.  Elucidating the Electrochemical Mechanism of NG-Hydroxy-L-arginine.

Authors:  Mariah L Arral; Christian Tooley; Emily Ziino; Jeffrey Mark Halpern
Journal:  J Electrochem Soc       Date:  2020-01-09       Impact factor: 4.316

8.  Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: therapeutic implications for neurodegenerative disorders.

Authors:  Arundhati Jana; Khushbu K Modi; Avik Roy; John A Anderson; Richard B van Breemen; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-09       Impact factor: 4.147

9.  Cinnamon Converts Poor Learning Mice to Good Learners: Implications for Memory Improvement.

Authors:  Khushbu K Modi; Suresh B Rangasamy; Sridevi Dasarathi; Avik Roy; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-24       Impact factor: 4.147

10.  Peritoneal dialysis in neonates with inborn errors of metabolism: is it really out of date?

Authors:  Ivana Pela; Daniela Seracini; Maria Alice Donati; Giancarlo Lavoratti; Elisabetta Pasquini; Marco Materassi
Journal:  Pediatr Nephrol       Date:  2007-09-26       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.